What is the primary goal of administering lactulose to a client with hepatic encephalopathy?

Hepatic encephalopathy is a neurologic complication of liver dysfunction caused by the accumulation of toxic substances, especially ammonia, in the bloodstream. When the liver is unable to effectively convert ammonia into urea for excretion, ammonia crosses the blood-brain barrier and affects brain function. This can lead to confusion, altered consciousness, and even coma. Lactulose is commonly administered to reduce serum ammonia levels and improve neurologic status. Rationale: A. Decreasing blood pressure is not the primary purpose of lactulose in hepatic encephalopathy. Lactulose acts mainly within the gastrointestinal tract and does not function as an antihypertensive medication. Although fluid shifts may occur with excessive diarrhea, blood pressure reduction is not its therapeutic target in this condition. B. Improving liver function tests is not the direct action of lactulose. The medication does not repair hepatocytes or restore liver enzyme levels such as AST, ALT, or bilirubin. Its benefit is focused on reducing neurotoxic ammonia accumulation rather than reversing the underlying hepatic damage shown in laboratory values. C. Enhancing the excretion of ammonia from the body is the primary goal of lactulose therapy. Lactulose acidifies the colon, converting ammonia (NH3) into ammonium (NH4+), which cannot be reabsorbed and is excreted in stool. Its laxative effect also decreases intestinal transit time, reducing ammonia production and absorption from the gut. D. Increasing sodium levels in the body is not the intended use of lactulose. It does not act as an electrolyte replacement therapy and may actually contribute to electrolyte imbalance if excessive diarrhea occurs. Sodium management in liver disease is addressed separately, especially in clients with ascites or fluid retention.